<div id="readability-page-1"><div><ul> <li>Early 2026, Gilead Sciences (NasdaqGS:GILD) has moved quickly on acquisitions of Arcellx, Ouro Medicines, and Tubulis.</li> <li>The company has also exercised exclusive licensing options with Cartography Biosciences for solid tumor targets and Kymera Therapeutics for a CDK2 molecular glue degrader.</li> <li>These deals expand Gilead's oncology and autoimmune pipelines and reduce reliance on its established HIV and legacy franchises.</li> </ul> <p>Gilead Sciences, trading at around $142.09, is drawing fresh attention as the market weighs this burst of deal activity against a share price that has returned 16.9% year to date and 43.9% over the past year. Over a 5 year period, the stock has delivered 160.3%. This puts the current moves into a longer term context for investors tracking how the business is evolving. The value score of 4 offers another data point for readers comparing Gilead to other large biopharma names.</p> <p>For investors, the recent acquisitions and licenses point to a company that is actively reshaping its pipeline mix toward oncology and advanced therapies such as cell therapy and targeted protein degradation. The key questions now center on how these new assets progress, how they fit with Gilead's existing capabilities, and what this could mean for the balance of revenue sources over time.</p> <p>Stay updated on the most important news stories for Gilead Sciences by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Gilead Sciences.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eb86f0e2-1916-439d-a4b8-74ce7ea1e1c9/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA0LTEw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eb86f0e2-1916-439d-a4b8-74ce7ea1e1c9/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA0LTEw"/><figcaption>NasdaqGS:GILD Earnings &amp; Revenue Growth as at Apr 2026</figcaption></figure> <p>We've flagged 1 risk for Gilead Sciences. See which could impact your investment.</p> <h3>Quick Assessment</h3> <ul> <li><strong>⚖️ Price vs Analyst Target</strong>: At US$142.09 versus an average analyst target of US$157.71, the price sits roughly 10% below consensus, suggesting modest upside based on those estimates.</li> <li><strong>✅ Simply Wall St Valuation</strong>: Shares are described as trading about 49.6% below an estimated fair value, which flags a meaningful valuation gap.</li> <li><strong>❌ Recent Momentum</strong>: The 30 day return of around 4.4% decline shows the share price has cooled despite the busy deal activity.</li> </ul> <p>There is only one way to know the right time to buy, sell or hold Gilead Sciences. Head to Simply Wall St's company report for the latest analysis of Gilead Sciences's Fair Value..</p> <h3>Key Considerations</h3> <ul> <li>📊 The cluster of oncology and platform deals pushes Gilead further into cell therapy and targeted protein degradation, which shifts the story beyond its HIV and legacy products.</li> <li>📊 Watch how acquired and partnered programs move through clinical milestones, as well as any updates to revenue, earnings and the current 20.7x P/E and 2.3% dividend yield.</li> <li>⚠️ Simply Wall St flags a high level of debt as a risk, which matters if acquisition and licensing spend continues at this pace.</li> </ul> <h3>Dig Deeper</h3> <p>For the full picture including more risks and rewards, check out the complete Gilead Sciences analysis. Alternatively, you can check out the community page for Gilead Sciences to see how other investors believe this latest news will impact the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

ACLX

<p>Gilead Sciences has made significant acquisitions, including Arcellx and Ouro Medicines, and secured licensing options with Cartography Biosciences and Kymera Therapeutics, shifting its focus towards oncology and advanced therapies. The company's stock, currently at $142.09, has seen a 16.9% year-to-date increase and a 43.9% rise over the past year. Analysts suggest a modest upside potential, with shares trading below fair value. However, concerns about high debt levels and recent stock price declines remain. Investors are encouraged to monitor clinical milestones and revenue updates.</p>

Gilead’s Deal Spree Shifts Pipeline Toward Oncology And Potential Upside